283 related articles for article (PubMed ID: 27432076)
1. Managing dyslipidaemia in type 2 diabetes mellitus.
Szalat A; Durst R; Leitersdorf E
Best Pract Res Clin Endocrinol Metab; 2016 Jun; 30(3):431-44. PubMed ID: 27432076
[TBL] [Abstract][Full Text] [Related]
2. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
3. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
[TBL] [Abstract][Full Text] [Related]
4. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
5. [Diabetic dyslipidaemia and the atherosclerosis].
Márk L; Dani G
Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
[TBL] [Abstract][Full Text] [Related]
6. Dyslipidemia in diabetes.
Kalra S; Raizada N
Indian Heart J; 2024 Mar; 76 Suppl 1(Suppl 1):S80-S82. PubMed ID: 37956957
[TBL] [Abstract][Full Text] [Related]
7. [HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia].
Bajnok L
Orv Hetil; 2014 Jan; 155(2):62-8. PubMed ID: 24389322
[TBL] [Abstract][Full Text] [Related]
8. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
9. What is the most effective strategy for managing diabetic dyslipidaemia?
Reasner CA
Atheroscler Suppl; 2005 Sep; 6(3):21-7. PubMed ID: 16054442
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms and Treatment of Dyslipidemia in Diabetes.
Bahiru E; Hsiao R; Phillipson D; Watson KE
Curr Cardiol Rep; 2021 Mar; 23(4):26. PubMed ID: 33655372
[TBL] [Abstract][Full Text] [Related]
11. [Dyslipemia in diabetics treated with statins. Results of the DYSIS study in Spian].
Millán J; Alegría E; Guijarro C; Lozano JV; Vitale GC; González-Timón B; González-Juanatey JR
Med Clin (Barc); 2013 Nov; 141(10):430-6. PubMed ID: 23246165
[TBL] [Abstract][Full Text] [Related]
12. Nonstatin therapies for management of dyslipidemia: a review.
Sando KR; Knight M
Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
[TBL] [Abstract][Full Text] [Related]
13. Management of dyslipidemia in people with type 2 diabetes mellitus.
Dunn FL
Rev Endocr Metab Disord; 2010 Mar; 11(1):41-51. PubMed ID: 20221703
[TBL] [Abstract][Full Text] [Related]
14. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].
Soska V
Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414
[TBL] [Abstract][Full Text] [Related]
15. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
Querton L; Buysschaert M; Hermans MP
J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
[TBL] [Abstract][Full Text] [Related]
16. Determinants of Achieved LDL Cholesterol and "Non-HDL" Cholesterol in the Management of Dyslipidemias.
Packard CJ
Curr Cardiol Rep; 2018 Jun; 20(8):60. PubMed ID: 29904807
[TBL] [Abstract][Full Text] [Related]
17. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Cardiovasc Diabetol; 2006 Sep; 5():20. PubMed ID: 17002798
[TBL] [Abstract][Full Text] [Related]
18. Interpreting clinical trials of diabetic dyslipidaemia: new insights.
Wierzbicki AS
Diabetes Obes Metab; 2009 Mar; 11(3):261-70. PubMed ID: 17645560
[TBL] [Abstract][Full Text] [Related]
19. Diabetic Dyslipidemia: Epidemiology and Prevention of Cardiovascular Disease and Implications of Newer Therapies.
Warraich HJ; Rana JS
Curr Cardiol Rep; 2018 Oct; 20(12):125. PubMed ID: 30311078
[TBL] [Abstract][Full Text] [Related]
20. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients.
Costet P; Hoffmann MM; Cariou B; Guyomarc'h Delasalle B; Konrad T; Winkler K
Atherosclerosis; 2010 Sep; 212(1):246-51. PubMed ID: 20619837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
